Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

M&A Pressure Mounts For Merck & Co After Alzheimer's Drug Dismissed

Executive Summary

Merck's verubecestat has flopped in a second Phase III Alzheimer's trial; investors are anticipating M&A or licensing deals soon to bring something new into the big pharma's development portfolio.

Advertisement

Related Content

Lilly Stays Committed To Alzheimer's, Including Amyloid Hypothesis, Despite Many Failures
Lilly/AstraZeneca's Lanabecestat Becomes Latest BACE Inhibitor Casualty
Eisai/Biogen Remain In BACE Race As Alzheimer's Contenders Dwindle
Pharmas Join To Build Inflammation Biomarkers In Alzheimer's, Depression
More Alzheimer's Pain As J&J Pulls Plug On BACE Inhibitor
Pharma Q1 Results Preview: Merck & Co, Pfizer, Gilead, Novo Nordisk, Teva, Celgene
Continuing Dismay In Alzheimer's: vTv's RAGE Antagonist Fails In Phase III Study
Get Ready For The Return Of The Mega-Merger, Leerink Says
Alzheimer's Biomarkers Gain Prominence In Drug Development Guidance
Another Nail In Amyloid Hypothesis Coffin? Merck Ends Pivotal BACE Inhibitor Study

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100397

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel